Advertisement
Canada markets close in 3 hours 58 minutes

  • S&P/TSX

    21,811.90
    -61.82 (-0.28%)
     

  • S&P 500

    5,017.67
    -53.96 (-1.06%)
     

  • DOW

    37,911.21
    -549.71 (-1.43%)
     

  • CAD/USD

    0.7303
    +0.0006 (+0.08%)
     

  • CRUDE OIL

    82.50
    -0.31 (-0.37%)
     

  • Bitcoin CAD

    87,783.83
    -656.65 (-0.74%)
     

  • CMC Crypto 200

    1,381.86
    -0.72 (-0.05%)
     

  • GOLD FUTURES

    2,342.70
    +4.30 (+0.18%)
     

  • RUSSELL 2000

    1,966.33
    -29.09 (-1.46%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ

    15,479.87
    -232.88 (-1.48%)
     

  • VOLATILITY

    16.73
    +0.76 (+4.76%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6811
    -0.0008 (-0.12%)
     
MARKETS LIVE BLOG:

STOCKS SLIDE AFTER META'S REALITY CHECK, WITH GDP ON DECK

Owner of Facebook and Instagram plans to spend up to US$10B on AI infrastructure investments

Medical Cannabis, and Biotech Stocks That Are Set to Explode

ACCESSWIRE

HENDERSON, NV / ACCESSWIRE / October 24, 2018 / The cannabis industry took a bit of a hit yesterday, making for several bounce opportunities we've highlighted below.

A fascinating biotech firm we discovered PPCB (Propanc Biopharma, Inc.) soared 7000% from late August to early September. PPCB has a 52 week high of $0.77 which would be an absolutely massive gain from the currently trading price. PPCB is currently preparing for its Phase 1 Clinical Trial of its lead product PRP, which was granted FDA Orphan Drug Designation for Pancreatic cancer. If this is the first time you are hearing about PPCB, start doing your own research now. PPCB is an impressive biotech firm, with an intriguing patent portfolio. PPCB recently released filed an S-1 registration statement for a $10M equity line. This is a major financing for such a small biotech company like PPCB, and PPCB could receive significantly increased attention from the street in the coming weeks. Anyone that find PPCB before the S-1 becomes effective, and clinical trial begins could be in store for an interesting ride.

A few companies to watch include: Propanc Biopharma, Inc. (PPCB), MariMed, Inc. (MRMD), Aurora Cannabis, Inc. (ACBFF), Aphria, Inc. (APHQF), and Puration, Inc. (PURA).

Propanc Biopharma, Inc. (PPCB)

Market Cap: $14.03M Share Price: $0.075

ADVERTISEMENT

Propanc Biopharma, Inc. (PPCB), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, just announced initiation of European (EP) validation of its lead patent in most major commercial markets in Europe. EP validation is the process of converting a single granted European patent application into a national patent in one or more contracting member and extension states of the European Patent Convention.

The Company's lead patent, which describes a pharmaceutical composition for treating cancer, is currently undergoing validation in 14 European countries - Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Turkey and the United Kingdom. Once validated, the Company will have the rights associated with a granted patent in each of these 14 European countries.

MariMed, Inc. (MRMD)

Market Cap: $810.2M Share Price: $4.15

MariMed, Inc., a professional cannabis organization that develops cannabis facilities and brands of cannabis infused products in multiple states throughout the US, announced it had consummated its strategic investment in Sprout, an all-in-one CRM and marketing software company for marijuana dispensaries and cannabis brands. This completes the previously announced MariMed LOI for investment in Cannabis Venture Partners, parent company of Sprout.

Aurora Cannabis, Inc. (ACBFF)

Market Cap: $9.56B Share Price: $9.96

The company released fiscal fourth-quarter earnings and confirmed its intention to list stock on a "senior" U.S. exchange such as the Nasdaq or the New York Stock Exchange.

Further to this on Friday, October 5, the company filed a Form-40 with the intent of registering its securities on the New York Stock Exchange. Aurora could join the ranks of a growing number of cannabis companies choosing to list on major exchanges in the US. Late last month, Canaccord Genuity raised its price target for Aurora Cannabis to 13 Canadian dollars from 11 Canadian dollars.

Aurora Chief Executive Terry Booth said, "This listing provides access to a broader investor audience who gain the opportunity to participate in our continued success."

Aphria, Inc. (APHQF)

Market Cap: $3.02B Share Price: $12.03

Aphria Inc. (APHQF) announced closing the acquisition of LATAM Holdings Inc. from Scythian Biosciences (SCCYF). The Transaction was funded by the assumption of US$1 million of existing LATAM Holdings debt with the remaining consideration funded by the issuance of 15,678,310 common shares of Aphria. The closing was pursuant to the terms of the definitive share purchase agreement previously announced by the Company on July 17, 2018.

Puration, Inc. (OTC PINK: PURA)

Market Cap: $6.37M Share Price: $0.12

Puration, Inc. announced initiating its first production run of an updated formula for its EVERx CBD Sports Water. This production run will also include the new EVERx labels. The Company introduced its CBD Sports Water at Arnold Schwarzenegger's Arnold Sports Festival early in 2017. Sales of EVERx have since grown 600%.

Important Disclaimer, Please Read:

The securities, investments, and industries referenced and impacted in the attached content, are risky investments, that can result in significant or entire loss. This article is not advice in making any speculative investment decision.

The attached content may include predictions, estimates or other information that might be considered forward-looking. While such forward-looking statements represent best judgment on what the future holds, at the time of first publishing, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on any forward-looking statements, that may be found in the attached content, as they only reflect as of the date of first publishing. Please keep in mind that authors, producers, disseminators are not obligated to revise or publicly release the results of any revision to any forward-looking statement, that may be found in the attached content, in light of new information or future events.

Regal Consulting LLC is hired by certain companies to increase awareness and disseminate material public information regarding the paying company. PPCB expects to pay forty thousand dollars for corporate awareness services for the month of October, and expects to continue to pay Regal to disseminate truthful and potentially material information regarding PPCB.

Regal Consulting LLC is not registered with FINRA or any other financial or securities regulatory authority, and does not provide investment advice. The attached content is not investment advice. Regal Consulting LLC is not a broker dealer.

Before making investment decisions, everyone, including viewers of this content, should seek advice and perform deep and thorough research.

Regal Consulting, LLC. may buy or sell additional shares of any company named, referenced, or impacted by information in the attached content, on the open market at any time, including before, during or after the publishing of the content. The amount of stock Regal may own in PPCB can be found updated here: http://www.regalconsultingllc.com/disclaimer/.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and ninety-five thousand two hundred dollars total by Regal Consulting. LLC, for news commentary articles for PPCB. PPCB and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. We may buy or sell additional shares of PPCB in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

For Full Legal Disclaimer Click Here.

Regal Consulting, LLC, For Full Legal Disclaimer Click Here.

Contact Information:
Company Name: Microcap Speculators
Contact Person: Media Manager
Email: info@microcapspecualtors.com
Phone: 1-702-720-6310
Country: United States
Website: http://microcapspeculators.com/

SOURCE: ACR Communication, LLC